Viatris (VTRS) Non-Current Deferred Tax Liability (2019 - 2026)
Viatris' (VTRS) quarterly Non-Current Deferred Tax Liability came in at $870.6 million in Q1 2026, down 19.58% year-on-year from $1.1 billion in Q1 2025, and down 2.4% quarter-over-quarter from $892.0 million in Q4 2025.
Viatris (VTRS) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Viatris' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $870.6 million for Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 19.58% year-over-year to $870.6 million in Q1 2026; TTM through Mar 2026 was $870.6 million, a 19.58% decrease from a year earlier, with the FY2025 full-year figure at $892.0 million, down 55.55% from the prior year.
- Non-Current Deferred Tax Liability retreated to $870.6 million in Q1 2026 per VTRS's latest filing, from $892.0 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $2.7 billion in Q1 2022 and bottomed at $870.6 million in Q1 2026.
- The 5-year median for Non-Current Deferred Tax Liability is $1.7 billion (2023), against an average of $1.8 billion.
- Across the five-year window, Non-Current Deferred Tax Liability increased 15.62% in 2024 and tumbled 55.55% in 2025, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $2.4 billion in 2022, then decreased by 28.63% to $1.7 billion in 2023, then advanced by 15.62% to $2.0 billion in 2024, then tumbled by 55.55% to $892.0 million in 2025, then fell by 2.4% to $870.6 million in 2026.
- Per Business Quant, the three latest VTRS Non-Current Deferred Tax Liability figures stand at $870.6 million (Q1 2026), $892.0 million (Q4 2025), and $1.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 870.60 Mn |
| Mar 31, 2026 | 870.60 Mn |
| Dec 31, 2025 | 892.00 Mn |
| Dec 31, 2025 | 892.00 Mn |
| Sep 30, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Dec 31, 2024 | 2.01 Bn |
| Dec 31, 2024 | 2.01 Bn |
| Sep 30, 2024 | 1.28 Bn |
| Sep 30, 2024 | 1.28 Bn |
| Jun 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.57 Bn |
| Mar 31, 2024 | 1.67 Bn |
| Mar 31, 2024 | 1.67 Bn |
| Dec 31, 2023 | 1.74 Bn |
| Dec 31, 2023 | 1.74 Bn |